GLMD is working to retest the $4.32 Levels of Resistance and if it's able to breakthrough and we find support at those price levels, we can expect this to move forward in retesting the $5.15 Price Ranges. The company is currently conducting Phase 3 Trials for their drug Aramchol, which focuses on Non-Alcoholic Steatohepatitis and Liver Fibrosis. The company also has a 2nd Drug in Phase 3 Trials, Amilo-5MER for Chronic Inflammatory Disorders. The company will be hosting a symposium to give an update on the pipeline for the continued development, progress of clinical trials, and manufacturing/distribution moving into the future. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.